Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results
2015 San Antonio Breast Cancer Symposium
Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Lisa A. Carey, MD, and Jay Harris, MD
Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
Benjamin D. Smith, MD
Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).
Matthew J. Ellis, PhD, FRCP
Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.
Lisa A. Carey, MD, and Kathy S. Albain, MD
Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer (Abstract S3-02).
Andrew Seidman, MD, and Hope S. Rugo, MD
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of a cooling cap to reduce hair loss during chemotherapy.